Morgan Stanley is offering accelerated returns from falls in the US small-cap Russell 2000 and a 10% cap on principal loss but the product's riskmap rating is above recent averages
Celfin Capital’s structured products business is thriving and market developments could boost volumes further, but its clients remain selective about where they put their money and prefer the familiarity...
Risk would like to invite you to join us on 14 April 2014 at 10am EST / 3pm GMT for our next FREE webinar. Joining the panel discussion will be: Moderator: Duncan Wood, Editor, RISK. Athanassios Diplas, Senior Advisor, ISDA. Barry Hadingham, Head of Derivatives and Counterparty Risk, AVIVA INVESTORS. Neil Murphy, Director, Collateral Product Management, IBM RISK ANALYTICS. Click to register.
More Clare Dickinson articles
Société Générale's product is likely to be used by those who have lost out on spread betting or equity investors wanting to boost returns.
Recent US structured products issuances have contained several products with multiple underlyings and the latest follows suit with basket products from HSBC, Barclays and Morgan Stanley.
Reverse convertibles are the product of choice in the latest issuance, Bank of Montreal has the lion's share.
HSBC's head of ETFs says the bank has no plans to create swap-based products and there should be steps to make structures clearer to investors.
ETF providers have been angered by the continuing focus on synthetic ETFs by regulators such as the Bank of England and the IMF. But they are particularly concerned about the bad press coverage.
Maturities for US structured products get stretched and Barclays issues a reverse convertible with a high risk rating
In response to industry fears of a collateral crunch, regulators have revised the proposed rules on margining for uncleared over-the-counter (OTC) derivatives.You can find out more by downloading this white paper here.
Hong Kong, 1st - 31st Dec 2014
Japan, 24th Apr 2014
Japan, 24th Apr 2014
USA, 30th Apr 2014
USA, 8th - 9th May 2014